FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2171008074> ?p ?o ?g. }

• W2171008074 endingPage "194" @default.
• W2171008074 startingPage "188" @default.
• W2171008074 abstract "In a cohort of 35 patients with multidrug-resistant and extensively drug-resistant tuberculosis, individually tailored bedaquiline-containing regimens led to culture conversion in 97% of patients after 6 months. Bedaquiline was discontinued in 2 (6%) patients for asymptomatic QTc interval prolongation. Background. Bedaquiline is a new antibiotic that was approved for the treatment of multidrug-resistant (MDR) tuberculosis. We aimed to evaluate the short-term microbiological efficacy and the tolerability profile of bedaquiline. Methods. We performed a retrospective cohort study among patients with MDR tuberculosis receiving bedaquiline for compassionate use between January 2010 and July 2013 and evaluated at 6 months of bedaquiline treatment. Results. A total of 35 patients with MDR tuberculosis were included in the study. Nineteen (54%) had extensively drug-resistant (XDR) tuberculosis, and 14 (40%) had isolates resistant to fluoroquinolones (Fqs) or second-line injectables. Bedaquiline was associated with a median of 4 (range, 2–5) other drugs, including linezolid in 33 (94%) cases. At 6 months of bedaquiline treatment, culture conversion was achieved in 28 of 29 (97%) cases with culture-positive pulmonary tuberculosis at bedaquiline initiation. Median time to culture conversion was 85 days (range, 8–235 days). Variables independently associated with culture conversion were treatment with a Fq (P = .01), absence of lung cavities (P < .001), and absence of hepatitis C virus infection (P = .001). A total of 7 patients (20%) experienced a ≥60-ms increase in QT interval, leading to bedaquiline discontinuation in 2 (6%) cases. Severe liver enzyme elevation occurred in 2 patients (6%). During the study period, 1 death (3%) occurred and was reported as unrelated to tuberculosis or antituberculosis treatment. Conclusions. The use of bedaquiline combined with other active drugs has the potential to achieve high culture conversion rates in complicated MDR and XDR tuberculosis cases, with a reassuring safety profile at 6 months of treatment." @default.
• W2171008074 created "2016-06-24" @default.
• W2171008074 creator A5020090769 @default.
• W2171008074 creator A5027618882 @default.
• W2171008074 creator A5035802687 @default.
• W2171008074 creator A5043752416 @default.
• W2171008074 creator A5044308727 @default.
• W2171008074 creator A5064837403 @default.
• W2171008074 creator A5072848204 @default.
• W2171008074 creator A5082324446 @default.
• W2171008074 creator A5087949981 @default.
• W2171008074 date "2014-10-15" @default.
• W2171008074 modified "2023-10-13" @default.
• W2171008074 title "Compassionate Use of Bedaquiline for the Treatment of Multidrug-Resistant and Extensively Drug-Resistant Tuberculosis: Interim Analysis of a French Cohort" @default.
• W2171008074 cites W1703307779 @default.
• W2171008074 cites W1971565905 @default.
• W2171008074 cites W2013159525 @default.
• W2171008074 cites W2021528843 @default.
• W2171008074 cites W2034077454 @default.
• W2171008074 cites W2051110950 @default.
• W2171008074 cites W2082757002 @default.
• W2171008074 cites W2084062265 @default.
• W2171008074 cites W2098793988 @default.
• W2171008074 cites W2103158311 @default.
• W2171008074 cites W2104750364 @default.
• W2171008074 cites W2109862905 @default.
• W2171008074 cites W2122198633 @default.
• W2171008074 cites W2135027892 @default.
• W2171008074 cites W2145611963 @default.
• W2171008074 cites W2147445933 @default.
• W2171008074 cites W2155742575 @default.
• W2171008074 cites W2156941948 @default.
• W2171008074 cites W2158658436 @default.
• W2171008074 cites W2159526017 @default.
• W2171008074 cites W2164282552 @default.
• W2171008074 cites W2164918529 @default.
• W2171008074 cites W2168509294 @default.
• W2171008074 cites W2169800706 @default.
• W2171008074 cites W2172065562 @default.
• W2171008074 cites W2318000940 @default.
• W2171008074 doi "https://doi.org/10.1093/cid/ciu786" @default.
• W2171008074 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/25320286" @default.
• W2171008074 hasPublicationYear "2014" @default.
• W2171008074 type Work @default.
• W2171008074 sameAs 2171008074 @default.
• W2171008074 citedByCount "147" @default.
• W2171008074 countsByYear W21710080742015 @default.
• W2171008074 countsByYear W21710080742016 @default.
• W2171008074 countsByYear W21710080742017 @default.
• W2171008074 countsByYear W21710080742018 @default.
• W2171008074 countsByYear W21710080742019 @default.
• W2171008074 countsByYear W21710080742020 @default.
• W2171008074 countsByYear W21710080742021 @default.
• W2171008074 countsByYear W21710080742022 @default.
• W2171008074 countsByYear W21710080742023 @default.
• W2171008074 crossrefType "journal-article" @default.
• W2171008074 hasAuthorship W2171008074A5020090769 @default.
• W2171008074 hasAuthorship W2171008074A5027618882 @default.
• W2171008074 hasAuthorship W2171008074A5035802687 @default.
• W2171008074 hasAuthorship W2171008074A5043752416 @default.
• W2171008074 hasAuthorship W2171008074A5044308727 @default.
• W2171008074 hasAuthorship W2171008074A5064837403 @default.
• W2171008074 hasAuthorship W2171008074A5072848204 @default.
• W2171008074 hasAuthorship W2171008074A5082324446 @default.
• W2171008074 hasAuthorship W2171008074A5087949981 @default.
• W2171008074 hasBestOaLocation W21710080741 @default.
• W2171008074 hasConcept C126322002 @default.
• W2171008074 hasConcept C141071460 @default.
• W2171008074 hasConcept C142724271 @default.
• W2171008074 hasConcept C167135981 @default.
• W2171008074 hasConcept C197934379 @default.
• W2171008074 hasConcept C2777768864 @default.
• W2171008074 hasConcept C2777975735 @default.
• W2171008074 hasConcept C2778375690 @default.
• W2171008074 hasConcept C2778715236 @default.
• W2171008074 hasConcept C2778980435 @default.
• W2171008074 hasConcept C2779489039 @default.
• W2171008074 hasConcept C2780544761 @default.
• W2171008074 hasConcept C2781069245 @default.
• W2171008074 hasConcept C2781414143 @default.
• W2171008074 hasConcept C2908628106 @default.
• W2171008074 hasConcept C523546767 @default.
• W2171008074 hasConcept C54355233 @default.
• W2171008074 hasConcept C71924100 @default.
• W2171008074 hasConcept C72563966 @default.
• W2171008074 hasConcept C86803240 @default.
• W2171008074 hasConceptScore W2171008074C126322002 @default.
• W2171008074 hasConceptScore W2171008074C141071460 @default.
• W2171008074 hasConceptScore W2171008074C142724271 @default.
• W2171008074 hasConceptScore W2171008074C167135981 @default.
• W2171008074 hasConceptScore W2171008074C197934379 @default.
• W2171008074 hasConceptScore W2171008074C2777768864 @default.
• W2171008074 hasConceptScore W2171008074C2777975735 @default.
• W2171008074 hasConceptScore W2171008074C2778375690 @default.
• W2171008074 hasConceptScore W2171008074C2778715236 @default.
• W2171008074 hasConceptScore W2171008074C2778980435 @default.
• W2171008074 hasConceptScore W2171008074C2779489039 @default.
• W2171008074 hasConceptScore W2171008074C2780544761 @default.

• next